LEARNING OBJECTIVES
After completing this activity, the primary care clinician will be better able to:
1. Define and broadly classify late-onset male hypogonadism
2. Describe the epidemiology of late-onset male hypogonadism
3. Describe the key signs and symptoms suggesting late-onset male hypogonadism
4. Identify the role of lab measurements, including total testosterone (T), free T, and bioavailable T, in the clinical diagnosis
5. List the goals of testosterone replacement therapy for late-onset male hypogonadism
6. List the factors to consider in selecting patients for testosterone replacement therapy
7. Describe the similarities and differences of the testosterone replacement therapy delivery systems
8. Identify a strategy to monitor safety and efficacy of, as well as patient adherence with, testosterone replacement therapy

TARGET AUDIENCE
Family physicians and clinicians who have an interest in treating patients with late-onset male hypogonadism.

SPONSOR DISCLOSURE STATEMENT
As a continuing medical education provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Primary Care Education Consortium (PCEC) to require any individual in a position to influence educational content to disclose the existence of any financial interest or other personal relationship with manufacturer(s) of any commercial product(s).

The content collaborators at the PCEC report no existing financial relationships to disclose.

Dr Brunton disclosed that he is on the speakers bureau of Boehringer-Ingelheim and Novo Nordisk, Inc. He is on the advisory boards for Amylin Pharmaceuticals, Inc., Kowa Pharmaceuticals America, Inc., and Novo Nordisk, Inc.

Dr Sadovsky disclosed that he is on the advisory board for Endo Pharmaceuticals, Inc.

The medical accuracy reviewer for this activity, Martin M. Miner, MD, disclosed that he is on the speakers bureau of Auxilium Pharmaceuticals, Inc. and Boehringer-Ingelheim. He receives contracted research support from GlaxoSmithKline.

The CME reviewer for this activity, Allan J. Wilke, MD, has no real or apparent conflicts of interest to report.

CONFLICT OF INTEREST STATEMENT
When individuals in a position to control content have reported financial relationships with one or more commercial interests, PCEC works with them to resolve such conflicts to ensure that the content presented is free of commercial bias. The content of the publication was vetted by the following mechanisms and modified as required to meet this standard:
• Content peer review by an external topic expert
• Content peer review by an external CME reviewer
• Content validity by internal PCEC clinical editorial staff

This supplement to The Journal of Family Practice was supported by an educational grant from Endo Pharmaceuticals, Inc., and was submitted by the Primary Care Education Consortium. It has been edited and peer reviewed by The Journal of Family Practice.
HYPOGONADISM AND TESTOSTERONE REPLACEMENT THERAPY

**CASE STUDY.** The history reveals that Mr Williams began to notice a loss in his libido about 2 years ago, although he has not experienced any erectile dysfunction. He thought that this symptom was related to his T2DM, so he had not thought much of it until his wife voiced her concern a few weeks ago. Mr Williams reports that he has been walking and using the stairs more at work because he has “put on a few pounds” over the past year. He indicates that he has been sleeping well and has not been depressed. He admits to feeling frustrated at times while working around the house, as he has found he does not have the strength to do some of the things he used to do. For example,
he had some difficulty moving an extension ladder while painting the second story of his house a few weeks ago. On physical examination, there was no evidence of gynecomastia or galactorrhea. Mr William’s testes measured approximately 3.5 cm x 2.5 cm and he has diminished facial hair. The remainder of the physical exam was relatively unremarkable, with no retinopathy. His vital signs and reflexes were normal.

**Diagnosis**

As noted earlier, the nonspecific nature of the symptoms of LOMH present a challenge in the diagnosis. Consequently, the diagnosis of LOMH is based on both signs and symptoms and laboratory tests.

**History and physical examination**

Some signs and symptoms are suggestive of male hypogonadism, while others are less clearly associated. (TABLE 1) While no clear relationship between decreasing testosterone level and symptoms has been determined, Zitzmann et al did observe a general trend between decreasing testosterone level and increasing prevalence of groups of symptoms. (FIGURE) As experienced by Mr Williams, loss of libido and loss of vigor are the two symptoms often experienced first as testosterone levels decline with advancing age.

To facilitate taking the history, several questionnaires that focus on signs and symptoms of hypogonadism in post-pubertal men were developed. Two examples are the Androgen Deficiency in Aging Males (ADAM) by Morley et al, which has been used for a decade, and a more recent questionnaire developed by Rosen et al. The ADAM questionnaire consists of 10 questions that assess several domains of importance in diagnosing hypogonadism in men aged 40 years or older. The Rosen questionnaire assesses 7 domains: (1) physical function; (2) bodily signs and symptoms; (3) sexual function and libido; (4) sleep function; (5) mood and affective function; (6) memory and cognitive function; and (7) distress or bother associated with hypogonadism symptoms. Although helpful, the use of questionnaires is limited by the variability in symptoms among men with LOMH.

A directed physical examination complements the history. The amount and distribution of body hair, including the beard, should be assessed and losses such as male pattern baldness should be noted. The presence and extent of gynecomastia, as well as galactorrhea, which suggests hyperprolactinemia, should be evaluated. The size, firmness, and consistency of the testes should be noted, with shrinkage or softness suggesting hypogonadism. Although the prostate should be examined, it may be enlarged in older men, despite a low testosterone level.

**Laboratory testing**

Laboratory testing is essential to confirm a clinical diagnosis of LOMH, as well as to differentiate primary from secondary hypogonadism. Measurement of the serum total testosterone level is the easiest means of screening for LOMH. The total testosterone level includes 3 fractions: free, weakly bound to albumin, and tightly bound to SHBG. In young adult men, the average percentages are 2%, 68%, and 30%, respectively. Testosterone that is free or weakly bound to albumin constitutes biologically available testosterone.

The total testosterone level should be drawn between 7:00 AM and 11:00 AM, as it is highest at this time of day. The American Association of Clinical Endocrinologists identifies a total testosterone level below 200 ng/dL as low, while The Endocrine Society identifies 300 ng/dL as the threshold. An abnormal result necessitates a repeat test. If the testosterone level is confirmed as being low, LH and FSH levels should be obtained to differentiate

<table>
<thead>
<tr>
<th>TABLE 1</th>
<th>Symptoms and signs of androgen deficiency in men¹</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Suggestive</strong></td>
<td></td>
</tr>
<tr>
<td>• Incomplete sexual development, eunuchoidism, aspermia</td>
<td></td>
</tr>
<tr>
<td>• Reduced sexual desire (libido) and activity</td>
<td></td>
</tr>
<tr>
<td>• Decreased spontaneous erections</td>
<td></td>
</tr>
<tr>
<td>• Breast discomfort, gynecomastia</td>
<td></td>
</tr>
<tr>
<td>• Loss of body (axillary and pubic) hair, reduced shaving</td>
<td></td>
</tr>
<tr>
<td>• Very small, soft or shrinking testes (especially &lt;5 mL) (normal adult volume is 20 to 30 mL)</td>
<td></td>
</tr>
<tr>
<td>• Inability to father children, low or zero sperm counts</td>
<td></td>
</tr>
<tr>
<td>• Height loss, low trauma fracture, low bone mineral density</td>
<td></td>
</tr>
<tr>
<td>• Reduced muscle bulk and strength</td>
<td></td>
</tr>
<tr>
<td>• Hot flushes, sweats</td>
<td></td>
</tr>
<tr>
<td><strong>Association less clear</strong></td>
<td></td>
</tr>
<tr>
<td>• Decreased energy, motivation, initiative, aggressiveness, self-confidence</td>
<td></td>
</tr>
<tr>
<td>• Feeling sad or blue, depressed mood, dysthymia</td>
<td></td>
</tr>
<tr>
<td>• Poor concentration and memory</td>
<td></td>
</tr>
<tr>
<td>• Sleep disturbance, increased sleepiness</td>
<td></td>
</tr>
<tr>
<td>• Mild anemia (normochromic, normocytic, in the female range)</td>
<td></td>
</tr>
<tr>
<td>• Increased body fat, body mass index</td>
<td></td>
</tr>
<tr>
<td>• Diminished physical or work performance</td>
<td></td>
</tr>
</tbody>
</table>

1. Adapted with permission. Copyright 2006, the Endocrine Society.
Mr Williams’ blood test revealed the following:

- Total testosterone level: 285 ng/dL; repeat: 276 ng/dL (normal: ≥300 ng/dL)
- FSH level: 19 IU/L (normal: 1.0–12.0 IU/L)
- LH level: 13 IU/L (normal: 2.0–14.0 IU/L)

Based on these laboratory results and Mr Williams’ signs and symptoms, he is given a diagnosis of male hypogonadism, probably LOMH type.

Treatment

The combination of signs and symptoms of LOMH and a low testosterone level confirms the diagnosis of LOMH and is an indication to consider testosterone replacement therapy (TRT). Other factors must be considered to determine if TRT is appropriate for a specific individual. First, contraindications to TRT must be carefully investigated. TRT is not recommended for men with a history of breast cancer, untreated prolactinoma, a palpable prostate nodule or induration, or prostate-specific antigen (PSA) level >3 ng/mL.\(^1\)\(^,\)\(^2\)\(^,\)\(^14\) While a history of prostate cancer has been considered an absolute contraindication to TRT\(^2\)\(^,\)\(^3\), retrospective studies have demonstrated TRT to not result in PSA recurrence in up to 12 years following radical retropubic prostatectomy.\(^15\)\(^-\)\(^17\) In these patients, it is recommended that TRT be provided by a urologist or oncologist. Other conditions in which TRT is not recommended include erythrocytosis (hematocrit >50%), severe benign prostatic hyperplasia (BPH) (American Urological Association [AUA] score >19), untreated obstructive sleep apnea.\(^1\)\(^,\)\(^2\)\(^,\)\(^14\) Caution is advised for those with risk factors for obstructive sleep apnea, such as obesity or chronic lung disease, and those who have a history of myocardial infarction or coronary artery disease.\(^16\)\(^,\)\(^17\) Finally, along with a discussion of the anticipated benefits and risks of treatment, discussion of the need for chronic treatment and regular monitoring should be undertaken with the patient prior to initiating TRT.

The second factor to discuss with the patient is that the goals of TRT are to restore physiologic concentrations of testosterone to the normal range, as well as to induce and maintain secondary sex characteristics and to improve sexual function, sense of well-being, behavior, and bone mineral density.\(^1\)\(^,\)\(^14\) The third factor is to confirm the type(s) and impact

---

**FIGURE** General correlation between increasing symptom prevalence and decreasing testosterone level\(^10\)

[Graph showing correlation between testosterone levels and symptom prevalence]

Adapted with permission. Copyright 2006, The Endocrine Society.
of current symptoms, since not all signs and symptoms respond to TRT. Sexual symptoms and loss of libido generally require higher levels of testosterone repletion, while fatigue requires lower levels. In addition, the impact of symptoms must be weighed against the risks and costs of treatment.

**Efficacy of TRT**

More than 5 decades of data and clinical experience has demonstrated TRT’s ability to restore the blood testosterone level to the normal range and to improve a variety of other physiologic signs and symptoms. While TRT is effective in restoring the testosterone level, it should not be assumed that the initial dosage level will be successful in doing so. Grober et al observed that more than half of men treated had a total testosterone level <300 ng/dL with initial TRT. Consequently, increasing the dose is generally required to achieve the target testosterone level and improve symptoms. This can often be accomplished within several months, after which time the level usually remains stable over several years.

Numerous other benefits of TRT have been demonstrated, including improvements in libido, sexual function, bone mineral density, lean and fat body mass, and mood.

---

**TABLE 2**  Clinical pharmacology of some testosterone formulations

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Regimen</th>
<th>Pharmacokinetic profile</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>T enanthate or cypionate</td>
<td>100 mg/wk IM or 200 mg every 2 wk IM</td>
<td>After a single IM injection, serum T levels rise into the supraphysiologic range, then decline gradually into the hypogonadal range by the end of the dosing interval</td>
<td>Corrects symptoms of androgen deficiency, relatively inexpensive, if self-administered. Flexibility of dosing</td>
<td>Requires IM injection. Peaks and valleys in serum T levels</td>
</tr>
<tr>
<td>Nongenital transdermal system</td>
<td>1 or 2 patches, designed to nominally deliver 5-10 mg T over 24 h applied daily on nonpressure areas</td>
<td>Restores serum T, DHT, and E2 levels into the physiological male range</td>
<td>Ease of application, corrects symptoms of androgen deficiency and mimics the normal diurnal rhythm of T secretion. Lesser increase in hemoglobin than injectable esters</td>
<td>Serum T levels in some androgen-deficient men may be in the low-normal range; these men may need application of 2 patches daily. Skin irritation at the application site may be a problem for some patients</td>
</tr>
<tr>
<td>T gel</td>
<td>5-10 g T gel containing 50-100 mg T should be applied daily</td>
<td>Restores serum T and E2 levels into the physiological male range</td>
<td>Corrects symptoms of androgen deficiency, provides flexibility of dosing, ease of application, good skin tolerability</td>
<td>Potential of transfer to a female partner or child by direct skin-to-skin contact; moderately high DHT levels</td>
</tr>
<tr>
<td>Buccal, bioadhesive, T tablets</td>
<td>30 mg controlled release, bioadhesive tablets used twice daily</td>
<td>Absorbed from the buccal mucosa</td>
<td>Corrects symptoms of androgen deficiency in healthy, hypogonadal men</td>
<td>Gum-related adverse events in 16% of treated men</td>
</tr>
<tr>
<td>T pellets</td>
<td>Four to six 200-mg pellets implanted SC</td>
<td>Serum T peaks at 1 mo and then sustained in normal range for 4 to 6 mo</td>
<td>Corrects symptoms of androgen deficiency</td>
<td>Requires surgical incision for insertions; pellets may extrude spontaneously</td>
</tr>
</tbody>
</table>

E2, estradiol; DHT, dihydrotestosterone; T, testosterone.

Adapted with permission. Copyright 2006, The Endocrine Society.
Adverse events and risks

Evidence supporting the long-term safety of TRT has come primarily from clinical experience, as long-term studies have generally been limited to a few years of follow up. Hepatotoxicity is no longer a concern because the oral formulations that caused it are not available in the US. More common adverse events associated with TRT include acne and oily skin, as well as reduced spermatogenesis and fertility. A 10% to 15% increase in the hemoglobin and/or hematocrit level is also commonly observed; the latter may increase the risk for a thromboembolic event.

Uncommon adverse events associated with TRT are gynecomastia, male pattern baldness, hypertension, and worsening symptoms of BPH. For example, gynecomastia was observed in 2.5% and urinary symptoms (eg, nocturia, hesitancy, and urgency) in 3.7% of men treated with AndroGel over 3 years. Obstructive sleep apnea or severe congestive heart failure also can be worsened with TRT. Edema may occur in patients with preexisting cardiac, renal, or hepatic disease.

Concern regarding TRT has primarily focused on the prostate and the fear of causing prostate cancer. While small increases in the PSA level have occasionally been observed in hypogonadal men taking TRT, an international multidisciplinary panel concluded that in men without prostate cancer, “there is no conclusive evidence that testosterone therapy increases the risk of prostate cancer or benign prostatic hypertrophy . . . or will convert subclinical prostate cancer to clinically detectable prostate cancer” In fact, analysis by a different panel of 18 prospective studies involving 3886 men with incident prostate cancer and 6438 control subjects found no association between the risk of prostate cancer and serum concentrations of testosterone, free testosterone, and several other related hormones, with the exception of an inverse relationship with SHBG. Similarly, a study involving 44 hypogonadal men (aged 44 to 78 years) found no treatment-related change in prostate histology, median prostate levels of testosterone and dihydrotestosterone, gene expression, or cancer incidence or severity following 6 months of treatment with testosterone.

In men with locally advanced and/or metastatic prostate cancer, the international multidisciplinary panel concluded that “there is unequivocal evidence that testosterone can stimulate growth and aggravate symptoms.” However, as noted earlier, TRT has been successfully utilized in men following radical retropubic prostatectomy. Nonetheless, these recommendations point to the importance of laboratory testing prior to and during TRT. In addition, urological consultation should be considered if prostate abnormalities are detected, such as an AUA BPH symptom index score greater than 19, as this is suggestive of severe prostate symptoms.

When the clinician and patient have thoroughly discussed the risk-benefit ratio of TRT and appropriate expectations and requirements for replacement, a decision can be made about the type of TRT formulation to be used.

Testosterone formulations

The injectable, implantable, dermal, transdermal, and buccal testosterone formulations currently available in the US are safe and effective. The availability of several formulations for TRT enables individualization based on patient preference, dosing and monitoring requirements, adverse events, and cost.

Three testosterone formulations that permit dosing less frequently than every day are available, which may be advantageous where daily administration is problematic. Two of these, the cypionate (Depo-Testosterone, generics) and enanthate (Delatryptyl, generics) formulations, are administered via intramuscular injection and the third is available as implantable pellets (Testopel) placed every 4 to 6 months. While the intramuscular formulations are usually given every 1 to 2 weeks, wide fluctuations in the blood testosterone level occur between doses. Consequently, unwanted physiologic and emotional effects (eg, breast tenderness, hyperactivity, fatigue, depression, or anger) may be observed. Initiating therapy with a low dose and titrating slowly may lessen such unwanted effects.

Testosterone can be applied to the skin either as a gel or as a patch. The gel formulations (Androgel or Testim) are used more widely than other formulations of testosterone in the US. However, the 2 gel formulations are not interchangeable, principally because they are not bioequivalent and can produce different clinical and biochemical responses. Androgel is available in 2 forms (pump or packet) and can be applied to the shoulder, upper arm, or abdomen. Testim is available in 1 form and can be applied to the shoulder or upper arm. The prescribing information for the gel formulations includes a black box warning concerning secondary exposure, as there is a risk of contact transmission with the gel. The transdermal patch (AndroDerm) provides close approximation to the normal circadian plasma concentration of testosterone when applied in the evening. Should minor skin irritation occur, the use of a 0.1% triamcinolone cream (not ointment) applied prior to patch replacement can be helpful without affecting testosterone absorption.

A buccal formulation (Striant) applied twice daily causes testosterone to be absorbed through the buccal mucosa, thereby avoiding the hepatotoxicity associated with first-pass metabolism of oral formulations.
and mouth irritation, taste alteration, bitter taste, and headache are among the most common adverse events.45

Monitoring
The use of TRT requires baseline assessment and ongoing monitoring to prevent and reduce the adverse events and risks that may occur. Several sources provide guidance for baseline assessment and periodic monitoring for patients receiving TRT. (TABLE 3)1,14,18,19,38,45,46 Recommended assessments at baseline include total testosterone, PSA, hematocrit, hemoglobin, liver enzymes, and lipid profile. These same assessments, as well as for adherence, adverse events, and symptom response, must be performed periodically following initiation of TRT. While the target total testosterone level is generally in the middle of the physiologic range of 350 to 1050 ng/dL, some men respond well to a level in the low-to-normal range. Attention should be paid to monitoring for acne, gynecomastia, and breast tenderness1 because they can be disconcerting to the patient. Close monitoring of the prothrombin time/international normalized ratio is necessary when adding or modifying TRT in a patient being treated with an oral anticoagulant, as bleeding may occur. Similarly, blood glucose levels may be decreased in a patient with diabetes, thereby requiring closer monitoring of blood glucose.38

Summary
LOMH is frequently observed in primary care, with an increasing prevalence in older men. The diagnosis is based on a combination of mostly nonspecific signs and symp-

<table>
<thead>
<tr>
<th>TABLE 3</th>
<th>Monitoring testosterone replacement therapy</th>
<th>1,2,14,18,19,38,45,46</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>What to monitor</strong></td>
<td><strong>When to monitor</strong></td>
<td></td>
</tr>
<tr>
<td>Adherence</td>
<td>Baseline to identify potential issues, then at each visit</td>
<td></td>
</tr>
<tr>
<td>Adverse events—general</td>
<td>3 months after initiation, then annually</td>
<td></td>
</tr>
<tr>
<td>Adverse events—formulation-specific</td>
<td>Buccal: if there are taste alterations, examine gums and oral mucosa for irritation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Injectable: inquire about fluctuations in mood or libido and evaluate hematocrit to detect excessive erythrocytosis, especially in older patients</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Patch: look for signs of skin reaction at the application site</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gels: advise patients to cover the application site with clothing and wash the skin before having skin-to-skin contact because gels leave a residue of testosterone on the skin that can be transferred to a woman or child who comes in close contact</td>
<td></td>
</tr>
<tr>
<td>Bone mineral density (lumbar spine, femoral neck, or hip)</td>
<td>1 to 2 y after initiation in hypogonadal men with osteoporosis or low-trauma fracture</td>
<td></td>
</tr>
<tr>
<td>Hematocrit, hemoglobin</td>
<td>Baseline, 3 to 4 months, 12 months, then annually. If Hct &gt;50%, stop treatment until Hct falls to safe level, evaluate for hypoxia and sleep apnea, reinitiate at reduced dose</td>
<td></td>
</tr>
<tr>
<td>Lipid profile</td>
<td>Baseline, 6 to 12 months after initiation, then annually</td>
<td></td>
</tr>
<tr>
<td>Liver function</td>
<td>Baseline, periodically</td>
<td></td>
</tr>
<tr>
<td>Prostate</td>
<td>Digital rectal examination and prostate specific antigen measurement before initiating treatment, at 3 months, then according to guidelines</td>
<td></td>
</tr>
<tr>
<td>Symptom response</td>
<td>Every 3 to 4 months after initiation, then annually</td>
<td></td>
</tr>
<tr>
<td>Testosterone level</td>
<td>Baseline</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Transdermal gel: after 2 weeks of treatment</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3 months after initiation for:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Cypionate/enanthate: midway between injections</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Transdermal patch: 4 to 8 h after patch application</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Buccal tablet: immediately before application</td>
<td></td>
</tr>
</tbody>
</table>

Hct, hemocrit.
HYPOGONADISM AND TESTOSTERONE REPLACEMENT THERAPY

REFERENCES


Take the CME Evaluation Online: www.pceconsortium.org/JFPJuly2010TRT

S8 July 2010 | Vol 59, No 7 | Supplement to The Journal of Family Practice